Phase I Dose Escalation Study of Carboplatin to a Fixed Dose of Irinotecan as First-Line Treatment of Small Cell Lung Cancer

Publisher： Karger

E-ISSN： 2296-5262|27|3|280-284

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.27, Iss.3, 2004-07, pp. : 280-284

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dose Escalation Study of Amrubicin in Combination with Fixed-Dose Irinotecan in Patients with Extensive Small-Cell Lung Cancer

By  

Oncology, Vol. 74, Iss. 1-2, 2008-06 ,pp. : 7-11

Karger

Access to resources Recommend Favorite

Dose Escalation Study of Paclitaxel in Combination with Fixed-Dose Irinotecan in Patients with Advanced Non-Small Cell Lung Cancer (JCOG 9807)

By  

Oncology, Vol. 66, Iss. 2, 2004-05 ,pp. : 94-100

Karger

Access to resources Recommend Favorite

Phase II Study of First-Line Sequential Chemotherapy with Gemcitabine-Carboplatin Followed by Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 382-390

Karger

Access to resources Recommend Favorite

Paclitaxel, Epirubicin and Cyclophosphamide Combination in First-Line Treatment of Metastatic Breast Cancer: A Dose Escalation Study

By  

Oncology, Vol. 66, Iss. 3, 2004-06 ,pp. : 185-191

Karger

Access to resources Recommend Favorite

Survival Outcome of Inoperable Non-Small Cell Lung Cancer Patients Receiving Conventional Dose Epirubicin and Paclitaxel as First-Line Treatment

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 350-355

Karger

Access to resources Recommend Favorite